NTLA
Price
$11.74
Change
-$0.19 (-1.59%)
Updated
Sep 11 closing price
Capitalization
1.65B
54 days until earnings call
Intraday BUY SELL Signals
PRME
Price
$3.13
Change
-$0.22 (-6.57%)
Updated
Sep 11 closing price
Capitalization
566.8M
48 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

NTLA vs PRME

NTLA vs PRME Comparison Chart in %
View a ticker or compare two or three
VS
NTLA vs. PRME commentary
Sep 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NTLA is a Buy and PRME is a Hold.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NTLA($1.65B) has a higher market cap than PRME($567M). NTLA YTD gains are higher at: 30.590 vs. PRME (-9.798). PRME has higher annual earnings (EBITDA): -189.12M vs. NTLA (-408.24M). NTLA has more cash in the bank: 438M vs. PRME (47.5M). NTLA has less debt than PRME: NTLA (73.4M) vs PRME (112M). NTLA has higher revenues than PRME: NTLA (59.5M) vs PRME (4.07M).
NTLAPRMENTLA / PRME
Capitalization1.65B567M290%
EBITDA-408.24M-189.12M216%
Gain YTD30.590-9.798-312%
P/E RatioN/AN/A-
Revenue59.5M4.07M1,461%
Total Cash438M47.5M922%
Total Debt73.4M112M66%
FUNDAMENTALS RATINGS
NTLA vs PRME: Fundamental Ratings
NTLA
PRME
OUTLOOK RATING
1..100
6058
VALUATION
overvalued / fair valued / undervalued
1..100
25
Undervalued
33
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9895
PRICE GROWTH RATING
1..100
5649
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NTLA's Valuation (25) in the Biotechnology industry is in the same range as PRME (33) in the null industry. This means that NTLA’s stock grew similarly to PRME’s over the last 12 months.

NTLA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as PRME (100) in the null industry. This means that NTLA’s stock grew similarly to PRME’s over the last 12 months.

PRME's SMR Rating (95) in the null industry is in the same range as NTLA (98) in the Biotechnology industry. This means that PRME’s stock grew similarly to NTLA’s over the last 12 months.

PRME's Price Growth Rating (49) in the null industry is in the same range as NTLA (56) in the Biotechnology industry. This means that PRME’s stock grew similarly to NTLA’s over the last 12 months.

PRME's P/E Growth Rating (100) in the null industry is in the same range as NTLA (100) in the Biotechnology industry. This means that PRME’s stock grew similarly to NTLA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NTLAPRME
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
84%
Momentum
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
89%
MACD
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
86%
Advances
ODDS (%)
N/A
Bullish Trend 10 days ago
81%
Declines
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
89%
Aroon
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
85%
COMPARISON
Comparison
Sep 12, 2026
Stock price -- (NTLA: $11.74 vs. PRME: $3.13)
Brand notoriety: NTLA and PRME are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NTLA: 75% vs. PRME: 106%
Market capitalization -- NTLA: $1.65B vs. PRME: $566.8M
NTLA [@Biotechnology] is valued at $1.65B. PRME’s [@Biotechnology] market capitalization is $566.8M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $130.64B. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NTLA’s FA Score shows that 1 FA rating(s) are green while PRME’s FA Score has 1 green FA rating(s).

  • NTLA’s FA Score: 1 green, 4 red.
  • PRME’s FA Score: 1 green, 4 red.
According to our system of comparison, PRME is a better buy in the long-term than NTLA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NTLA’s TA Score shows that 3 TA indicator(s) are bullish while PRME’s TA Score has 5 bullish TA indicator(s).

  • NTLA’s TA Score: 3 bullish, 6 bearish.
  • PRME’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, PRME is a better buy in the short-term than NTLA.

Price Growth

NTLA (@Biotechnology) experienced а -7.85% price change this week, while PRME (@Biotechnology) price change was -15.41% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.09%. For the same industry, the average monthly price growth was -3.45%, and the average quarterly price growth was +2531.70%.

Reported Earning Dates

NTLA is expected to report earnings on Nov 05, 2026.

PRME is expected to report earnings on Oct 30, 2026.

Industries' Descriptions

@Biotechnology (-6.09% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
NTLA
Daily Signal:
Gain/Loss:
PRME
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
AMAJX12.150.09
+0.75%
American Century Small Cap Dividend R
FDYZX211.25N/A
N/A
Franklin DynaTech Adv
PIDIX15.55N/A
N/A
Principal International EQ Index Instl
AIQQX22.05N/A
N/A
Aristotle Value Equity I-2
FFUZX126.53N/A
N/A
Fidelity Advisor Utilities Z

NTLA and

Correlation & Price change

A.I.dvisor indicates that over the last year, NTLA has been closely correlated with VCYT. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if NTLA jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NTLA
1D Price
Change %
NTLA100%
-1.59%
VCYT - NTLA
69%
Closely correlated
-2.76%
CRSP - NTLA
61%
Loosely correlated
-1.03%
BEAM - NTLA
60%
Loosely correlated
-1.56%
PRME - NTLA
58%
Loosely correlated
-6.57%
EDIT - NTLA
56%
Loosely correlated
+1.89%
More

PRME and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRME has been closely correlated with CRSP. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if PRME jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRME
1D Price
Change %
PRME100%
-6.57%
CRSP - PRME
69%
Closely correlated
-1.03%
BEAM - PRME
65%
Loosely correlated
-1.56%
RXRX - PRME
64%
Loosely correlated
+1.27%
EDIT - PRME
61%
Loosely correlated
+1.89%
NTLA - PRME
55%
Loosely correlated
-1.59%
More